

ImproveCareNow Research Prioritization Topics

1	Do the effects of dual therapy differ for patients who start both treatments at the same time versus those who start biologics then step-up to dual therapy?
2	What are the characteristics (i.e. IBD phenotype and patient demographics, treatment course) of children who are unable to achieve remission within the first two years of being diagnosed?
3	What are the IBD and patient characteristics that should influence decision-making on the most effective treatments?
4	Compare the effectiveness of biologic agents (e.g., Infliximab, adalimumab) vs. enteral feeds to decrease inflammation
5	What is the comparative effectiveness of enteral therapy versus medications for treatment of IBD?
6	Compare risks for malignancy (cancer) for different treatments (immunosuppressants vs. monoclonal antibody therapy vs. steroids. vs. others)
7	How are long-term clinical and health outcomes influenced by patient, family, environmental, and IBD treatment characteristics?
8	Are probiotics and prebiotics effective in reducing the symptoms of IBD and/or reduction in disease severity?
9	What are the best ways to help children with IBD track their symptoms? How can we help them figure out what they do (e.g. exercise) or eat (e.g. types of food) makes them feel better or worse?
10	How do children's levels of emotional distress and subjective well-being impact how well their treatments work to reduce IBD symptoms?
11	What are the best ways to diagnose symptoms of IBD that show up outside of the intestines - eczema, psoriasis, skin rashes and arthritis (swelling, pain, stiffness of the joints) - and determine whether they are medication side effects?
12	What are the best ways to screen and address psychosocial health concerns (e.g., depression) that may co-occur with IBD?
13	Compare the effectiveness of different immunosuppressants (for example, methotrexate (MTX) vs. Azathioprine (AZA) vs. 6-mercaptopurine (6MP))

14	How effective is a low sugar and/or carbohydrate diet (i.e. SCD) in reducing the symptoms and disease markers of IBD in outcomes?
15	What are the best ways to help children with IBD and their parents provide accurate reports of symptoms? How can we help them communicate better with doctors when symptoms change?
16	How can we help children with IBD deal with the ways that their disease impacts their social lives and relationships with friends?
17	What are the best ways to share information about IBD with patients and families? How can doctors make sure that children and families are involved in making decisions about their/their child's health and health care?
18	What are the best ways to help children with IBD and their parents take care of their health and manage their disease in the ways that doctors and other healthcare professionals suggest?
19	When children are coming off of enteral nutrition therapy, does limiting their diet help children to stay symptom free?
20	How does the pain that children with IBD experience vary by disease severity and other patient and disease characteristics?
21	How does fatigue vary by disease, patient, and environmental characteristics?
22	What are the effects of steroid/placebo versus steroid/Xifaxan in newly diagnosed, treatment naive, IBD?